Entera Bio (ENTX) Net Cash Flow (2021 - 2026)

Entera Bio has disclosed Net Cash Flow across 6 years of filings, most recently posting -$3.0 million for Q1 2026.

• Quarterly Net Cash Flow fell 124.82% year-over-year to -$3.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$8.7 million (down 175.81% YoY) and the FY2025 annual result came in at $6.2 million, up 365.8% from the prior year.
• Net Cash Flow declined to -$3.0 million in Q1 2026, from -$1.7 million in the prior quarter.
• Over five years, Net Cash Flow peaked at $11.9 million in Q1 2025 and troughed at -$4.8 million in Q1 2022.
• A 5-year average of -$761823.5 and a median of -$1.7 million in 2025 frame the typical range for Net Cash Flow.
• Biggest YoY gain for Net Cash Flow was 750.93% in 2025; the steepest drop was 1337.82% in 2025.
• Tracing ENTX's Net Cash Flow over 5 years: stood at -$2.0 million in 2022, then surged by 269.27% to $3.4 million in 2023, then sank by 48.75% to $1.7 million in 2024, then slumped by 196.51% to -$1.7 million in 2025, then sank by 75.56% to -$3.0 million in 2026.
• Business Quant data shows ENTX's Net Cash Flow at -$3.0 million in Q1 2026, -$1.7 million in Q4 2025, and -$2.3 million in Q3 2025.